Clinical Trial Goal
To find out:
- The highest dose of OPN-6602 that's safe to give
- If OPN-6602 is safe and works well to treat multiple myeloma that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years or older
- Have multiple myeloma that has relapsed or is refractory
- Do not have any of the following:
- IgM myeloma
- Monoclonal gammopathy of undetermined significance (MGUS)
- POEMS syndrome
- Smoldering myeloma
- Waldenstrom's macroglobulinemia
- Have not had allogeneic (cells from a donor) blood or marrow transplant (BMT) in the last 1 year
- Have not had autologous (your own cells) BMT in the last 3 months
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
OPN-6602 is a small molecule inhibitor that blocks CBP bromodomain and EP300 in certain cells.
You’ll get:
You’ll get:
- OPN-6602 – A pill that you take by mouth 1 time each day
You'll have biopsies to see how well the treatment is working.
The Food and Drug Administration (FDA) has not yet approved OPN-6602.
Locations
Sponsors
lead: Opna Bio LLC
